IDEXX Laboratories, Inc. says it will expand its canine cancer testing with two additions. Mast cell tumour detection will be added to the IDEXX Cancer Dx Panel in Canada and the United States starting mid-2026, and FNA cytology for mast cell tumours will be introduced on the inVue Dx Cellular Analyzer as of late Q4 2025.

The company says the expanded Cancer Dx Panel will allow veterinarians to screen at-risk dogs during wellness exams and test patients with suspected mast cell tumours. More than 5,500 practices currently use the panel’s lymphoma test, which IDEXX says can detect that cancer up to eight months before clinical signs appear.

Mast cell tumour results will be available in two to three days, or two to four days in Canada, with no changes to workflow.

The inVue Dx analyzer’s new FNA cytology feature will let veterinarians assess skin masses, identify and quantify cells, and provide in-clinic results while owners are present.

Pathologist review can be requested without preparing a slide. IDEXX says the cytology menu will expand beyond mast cell tumours over time.

Mast cell tumours are among the most common cancers in dogs and can resemble benign lesions, making cellular analysis essential.

IDEXX says the combined tools aim to support more proactive screening and faster diagnosis.

The new lab testing will be available mid‑2026. The lymphoma test remains available in North America.

For more information, visit the IDEXX cancer diagnostics webpage.